Convenient dosing that may fit into their routine

Once-daily TAGRISSO can be taken any time of day,* with or without food¹

One 80-mg tablet once a day

Pill image is not actual size.

With or without food

The starting dose for TAGRISSO is 80 mg orally once a day

TAGRISSO comes in 2 prescription strengths, 80 mg and 40 mg

TAGRISSO can be taken with or without food—whichever your patient prefers
Remind your patients about the importance of taking TAGRISSO at the same time every day
If your patient misses a dose, they should be instructed to not make up the dose. Tell your patient to take the next dose as scheduled

*At the same time each day.

Convenient dosing that may fit into their routine

For patients who have difficulty swallowing pills¹

Disperse tablet in 60 mL (2 ounces) of non-carbonated water only
Then stir until tablet is dispersed into small pieces (the tablet will not completely dissolve), and swallow immediately
The tablet should not be crushed, heated, or ultrasonicated during preparation
Patients should rinse the container with 120 mL to 240 mL (4 to 8 ounces) of water and immediately drink
TAGRISSO can be dissolved in water and swallowed or given through an NG tube. For administration via NG tube, please see the complete Prescribing Information

EGFRm, epidermal growth factor receptor mutant; NG, nasogastric; NSCLC, non-small cell lung cancer.

Reference: 1. TAGRISSO [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.

IMPORTANT SAFETY INFORMATION

There are no contraindications for TAGRISSO
Interstitial lung disease (ILD)/pneumonitis occurred in 3.9% of the 1142 TAGRISSO-treated patients; 0.4% of cases were fatal. Withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (eg, dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD is confirmed
Heart rate-corrected QT (QTc) interval prolongation occurred in TAGRISSO-treated patients. Of the 1142 TAGRISSO-treated patients in clinical trials, 0.9% were found to have a QTc >500 msec, and 3.6% of patients had an increase from baseline QTc >60 msec. No QTc-related arrhythmias were reported. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia
Cardiomyopathy occurred in 2.6% of the 1142 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ≥10% from baseline and to <50% LVEF occurred in 3.9% of 908 patients who had baseline and at least one follow-up LVEF assessment. Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO
Keratitis was reported in 0.7% of 1142 patients treated with TAGRISSO in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist
Postmarketing cases consistent with Stevens-Johnson syndrome (SJS) and erythema multiforme major (EMM) have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if SJS or EMM is suspected and permanently discontinue if confirmed
Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the final dose
Most common adverse reactions (≥20%) were diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue and decreased appetite

INDICATION

TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Please see complete Prescribing Information including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.